The role of common genetic variation in presumed monogenic epilepsies
- PMID: 35679801
- PMCID: PMC9188960
- DOI: 10.1016/j.ebiom.2022.104098
The role of common genetic variation in presumed monogenic epilepsies
Abstract
Background: The developmental and epileptic encephalopathies (DEEs) are the most severe group of epilepsies which co-present with developmental delay and intellectual disability (ID). DEEs usually occur in people without a family history of epilepsy and have emerged as primarily monogenic, with damaging rare mutations found in 50% of patients. Little is known about the genetic architecture of patients with DEEs in whom no pathogenic variant is identified. Polygenic risk scoring (PRS) is a method that measures a person's common genetic burden for a trait or condition. Here, we used PRS to test whether genetic burden for epilepsy is relevant in individuals with DEEs, and other forms of epilepsy with ID.
Methods: Genetic data on 2,759 cases with DEEs, or epilepsy with ID presumed to have a monogenic basis, and 447,760 population-matched controls were analysed. We compared PRS for 'all epilepsy', 'focal epilepsy', and 'genetic generalised epilepsy' (GGE) between cases and controls. We performed pairwise comparisons between cases stratified for identifiable rare deleterious genetic variants and controls.
Findings: Cases of presumed monogenic severe epilepsy had an increased PRS for 'all epilepsy' (p<0.0001), 'focal epilepsy' (p<0.0001), and 'GGE' (p=0.0002) relative to controls, which explain between 0.08% and 3.3% of phenotypic variance. PRS was increased in cases both with and without an identified deleterious variant of major effect, and there was no significant difference in PRS between the two groups.
Interpretation: We provide evidence that common genetic variation contributes to the aetiology of DEEs and other forms of epilepsy with ID, even when there is a known pathogenic variant of major effect. These results provide insight into the genetic underpinnings of the severe epilepsies and warrant a shift in our understanding of the aetiology of the DEEs as complex, rather than monogenic, disorders.
Funding: Science foundation Ireland, Human Genome Research Institute; National Heart, Lung, and Blood Institute; German Research Foundation.
Keywords: DEEs; Epilepsy; Genetic diagnostics; PRS.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of interests Dennis Lal received research support from Taysha Therapeutics via his institution, received consulting fees from Encoded Therapeutics and honoraria for lectures from Stoke Therapeutics. Gianpiero Cavalleri received grant funding from Janssen Pharmaceuticals and Congenica for projects not directly related to this manuscript. Ingrid Scheffer received consulting fees from Atheneum Partners, Care Beyond Diagnosis, Epilepsy Consortium, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, honoraria for lectures or presentations from Athena Diagnostics, Biocodex, BioMarin, Chiesi, Eisai, GlaxoSmithKline, Liva Nova, UCB, support to attend meeting from Biocodex, BioMarin, Eisai, GlaxoSmithKline and UCB, has two patents WO/2006/13358 and WO/2013/059884 and a pending patent WO/2009/086591, participates on the journal board of The Lancet Neurology, Progress in Epileptic Disorders series, Epilepsy Currents, Epileptic Disorders and Neurology, is on the Scientific Advisory Board of BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Takeda Pharmaceuticals, UCB, Xenon Pharmaceuticals, is the non executive director of BellberryLtd and is a trial investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharmaceuticals, Marinus Pharmaceuticals, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix, Zynerba Pharmaceuticals. Norman Delanty received grants or contracts from GW Pharma, Uneeg, IIP Novartis. Stefan Wolking received grants or contracts from the German Research Foundation for projects not directly related to this manuscript, honoraria for speaker fees from Angelini, support for travel from Eisai and Angelini, is the president of the German Epilepsy Society (ILAE Branch) – Commission for Epilepsy and Genetics. Yen-Chen Anne Feng is supported by the “National Taiwan University Higher Education Sprout Project (NTU-110L8810)” within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. Holger Lerche received grants from the German Research Foundation, the Federal Ministry for Education and research, Else-Kröner Fresenius Foundation, Bial, Boehringer Ingelheim for projects not directly related to this manuscript, consulting fees from Bial, Eisai, UCB/Zogenix, Arvelle/Angelini Pharma, honoraria for lectures from Bial, Eisai, UCB/Zogenix, Desitin, support for attending meetings and/or travel from Bial, Eisai, UCB/Zogenix, Desitin, participated on the data safety and monitoring board of IntraBio, chaired the Genetics Commission of the ILAE. The other authors have no conflicts of interest to report.
Figures


Similar articles
-
Common risk variants for epilepsy are enriched in families previously targeted for rare monogenic variant discovery.EBioMedicine. 2022 Jul;81:104079. doi: 10.1016/j.ebiom.2022.104079. Epub 2022 May 27. EBioMedicine. 2022. PMID: 35636315 Free PMC article.
-
Investigating the effect of polygenic background on epilepsy phenotype in 'monogenic' families.EBioMedicine. 2024 Nov;109:105404. doi: 10.1016/j.ebiom.2024.105404. Epub 2024 Oct 30. EBioMedicine. 2024. PMID: 39476534 Free PMC article.
-
Polygenic burden in focal and generalized epilepsies.Brain. 2019 Nov 1;142(11):3473-3481. doi: 10.1093/brain/awz292. Brain. 2019. PMID: 31608925 Free PMC article.
-
Genome-Wide Insights and Polygenic Risk Scores in Common Epilepsies: A Narrative Review.Am J Med Genet B Neuropsychiatr Genet. 2025 Jun 13:e33040. doi: 10.1002/ajmg.b.33040. Online ahead of print. Am J Med Genet B Neuropsychiatr Genet. 2025. PMID: 40511554 Review.
-
Copy number variants are frequent in genetic generalized epilepsy with intellectual disability.Neurology. 2013 Oct 22;81(17):1507-14. doi: 10.1212/WNL.0b013e3182a95829. Epub 2013 Sep 25. Neurology. 2013. PMID: 24068782 Free PMC article. Review.
Cited by
-
Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.Nat Commun. 2024 Jul 25;15(1):6277. doi: 10.1038/s41467-024-50295-z. Nat Commun. 2024. PMID: 39054313 Free PMC article.
-
Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.medRxiv [Preprint]. 2023 Nov 27:2023.11.27.23297542. doi: 10.1101/2023.11.27.23297542. medRxiv. 2023. Update in: Nat Commun. 2024 Jul 25;15(1):6277. doi: 10.1038/s41467-024-50295-z. PMID: 38076931 Free PMC article. Updated. Preprint.
-
Clinical features and underlying etiology of children with Lennox-Gastaut syndrome.J Neurol. 2024 Aug;271(8):5392-5401. doi: 10.1007/s00415-024-12465-3. Epub 2024 Jul 15. J Neurol. 2024. PMID: 39008035
-
Strain-dependent effects on neurobehavioral and seizure phenotypes in Scn2aK1422E mice.bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543929. doi: 10.1101/2023.06.06.543929. bioRxiv. 2023. PMID: 37333275 Free PMC article. Preprint.
-
Inflation of polygenic risk scores caused by sample overlap and relatedness: Examples of a major risk of bias.Am J Hum Genet. 2024 Sep 5;111(9):1805-1809. doi: 10.1016/j.ajhg.2024.07.014. Epub 2024 Aug 20. Am J Hum Genet. 2024. PMID: 39168121 Free PMC article.
References
-
- Nabbout R, Dulac O. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol [Internet] 2003;20(6) https://journals.lww.com/clinicalneurophys/Fulltext/2003/11000/Epileptic... Available from. - PubMed
-
- Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain. 2021;144(February 1):32–43. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources